Compare SBH & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBH | CAPR |
|---|---|---|
| Founded | 1964 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2006 | 2011 |
| Metric | SBH | CAPR |
|---|---|---|
| Price | $13.88 | $34.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $17.25 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 1.2M | 860.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.17 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $3,701,424,000.00 | N/A |
| Revenue This Year | $2.20 | N/A |
| Revenue Next Year | $1.82 | $3.31 |
| P/E Ratio | $30.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.12 | $4.30 |
| 52 Week High | $17.92 | $40.37 |
| Indicator | SBH | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 55.34 |
| Support Level | $13.14 | $22.09 |
| Resistance Level | $15.75 | $36.66 |
| Average True Range (ATR) | 0.57 | 2.04 |
| MACD | -0.07 | -0.28 |
| Stochastic Oscillator | 24.40 | 58.25 |
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. The company operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, Netherlands, and other geographical regions. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. The products offered by the company include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.